Study summary · research use only
Impaired Follistatin Secretion in Cirrhosis
Plain-language summary
Paraphrased from the published abstract below — not a verdict on whether anything works.
In this human study, researchers compared eight male patients with liver cirrhosis to eight healthy control participants to examine the capacity for acute follistatin release. Participants received 1-hour glucagon/somatostatin infusions and separate saline infusions, with follistatin measured during and 5 hours after infusion. The peak follistatin change was reported as significantly decreased in the cirrhosis group compared to controls (1.9, interquartile range 1.4-2.5, versus 3.6, interquartile range 3.0-4.0; P = .003). Patients with cirrhosis also had significantly decreased appendicular lean mass compared to controls (27.6 ± 3.8% versus 34.5 ± 2.9%; P = .001). The authors state these findings indicate impaired capacity to acutely secrete follistatin in cirrhosis, which they suggest may contribute to muscle loss in this condition.
Abstract
Follistatin is a liver-derived inhibitor of the muscle-growth inhibitor myostatin. Reduction in acute follistatin release may help explain muscle loss in liver cirrhosis. The study aimed to investigate the capacity of acute follistatin release in patients with liver cirrhosis compared to healthy control participants. To experimentally increase the glucagon-insulin ratio (mimicking the hormonal effect of exercise), we infused glucagon/somatostatin (to inhibit insulin secretion) and compared the acute follistatin increase in eight male cirrhosis patients with eight healthy control participants. Patients and controls received 1-hour glucagon/somatostatin and saline infusions on 2 separate days. Follistatin was measured during and 5 hours after termination of infusions. The peak follistatin change was significantly decreased in patients with liver cirrhosis compared to healthy control participants (1.9 (interquartile range, 1.4-2.5) versus 3.6 (interquartile range, 3.0-4.0), respectively; P = .003). Patients with liver cirrhosis demonstrated significantly decreased amounts of appendicular lean mass compared to healthy controls (27.6 ± 3.8 vs 34.5 ± 2.9%, respectively; P = .001). Patients with cirrhosis show impaired capacity to acutely secrete follistatin. The decrease in acute follistatin release may contribute to the loss of muscle mass in liver cirrhosis.
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow the citation to its source and read it yourself. Research use only.